Association of QT interval-prolonging drugs with clinical trial eligibility in patients with advanced cancer.

ABSTRACT:

Introduction

Drug-induced prolongation of the heart rate-corrected QT interval (QTc) is associated with increased risk for the potentially fatal arrhythmia torsades de pointes. Due to arrhythmia risk, clinical trials with cancer therapeutics often exclude patients based on thresholds for QTc prolongation. Our objective was to assess associations between prescriptions for QT-prolonging drugs and the odds of meeting cancer trial exclusionary QTc thresholds in a cohort of adults with advanced cancer.

Methods

Electronic health records were retrospectively reviewed for 271 patients seen at our institutional molecular solid tumor clinic. Collected data included demographics, QTc measurements, ventricular arrhythmia-related diagnoses, and all inpatient and outpatient prescriptions.

SUBMITTER: Rowe EJ 

PROVIDER: S-EPMC9798408 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature